These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 24008572

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Response to letter regarding article, "Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation".
    Hori M, Ezekowitz MD, Reilly PA.
    Stroke; 2014 Mar; 45(3):e43. PubMed ID: 24473183
    [No Abstract] [Full Text] [Related]

  • 3. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation.
    Hori M, Connolly SJ, Zhu J, Liu LS, Lau CP, Pais P, Xavier D, Kim SS, Omar R, Dans AL, Tan RS, Chen JH, Tanomsup S, Watanabe M, Koyanagi M, Ezekowitz MD, Reilly PA, Wallentin L, Yusuf S, RE-LY Investigators.
    Stroke; 2013 Jul; 44(7):1891-6. PubMed ID: 23743976
    [Abstract] [Full Text] [Related]

  • 4. Atrial fibrillation: A promising new anticoagulant for stroke prevention.
    Spinler SA.
    Nat Rev Cardiol; 2010 Jan; 7(1):10-1. PubMed ID: 20019756
    [No Abstract] [Full Text] [Related]

  • 5. Response to letter regarding article, "Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control".
    Chan PH, Hai JJ, Siu CW.
    Stroke; 2015 Mar; 46(3):e72. PubMed ID: 25649808
    [No Abstract] [Full Text] [Related]

  • 6. Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control.
    Ho CW, Ho MH, Chan PH, Hai JJ, Cheung E, Yeung CY, Lau KK, Chan KH, Lau CP, Lip GY, Leung GK, Tse HF, Siu CW.
    Stroke; 2015 Jan; 46(1):23-30. PubMed ID: 25406148
    [Abstract] [Full Text] [Related]

  • 7. Letter by Feng et al regarding article, "Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control".
    Feng X, Huan Y, Lv Y.
    Stroke; 2015 Mar; 46(3):e71. PubMed ID: 25649800
    [No Abstract] [Full Text] [Related]

  • 8. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
    Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, Sheu TC, Mott K, Goulding MR, Houstoun M, MaCurdy TE, Worrall C, Kelman JA.
    Circulation; 2015 Jan 13; 131(2):157-64. PubMed ID: 25359164
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation.
    Ezekowitz MD, Wallentin L, Connolly SJ, Parekh A, Chernick MR, Pogue J, Aikens TH, Yang S, Reilly PA, Lip GY, Yusuf S, RE-LY Steering Committee and Investigators.
    Circulation; 2010 Nov 30; 122(22):2246-53. PubMed ID: 21147728
    [Abstract] [Full Text] [Related]

  • 12. Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial.
    Paikin JS, Haroun MJ, Eikelboom JW.
    Expert Rev Cardiovasc Ther; 2011 Mar 30; 9(3):279-86. PubMed ID: 21438804
    [Abstract] [Full Text] [Related]

  • 13. Dabigatran versus warfarin for patients with non-valvular atrial fibrillation: is the patient the winner?
    Grave S.
    Aust Nurs J; 2011 Mar 30; 19(6):30-3. PubMed ID: 22329103
    [Abstract] [Full Text] [Related]

  • 14. Dabigatran Versus Warfarin for Atrial Fibrillation in Real-World Clinical Practice: A Systematic Review and Meta-Analysis.
    Romanelli RJ, Nolting L, Dolginsky M, Kym E, Orrico KB.
    Circ Cardiovasc Qual Outcomes; 2016 Mar 30; 9(2):126-34. PubMed ID: 26812933
    [Abstract] [Full Text] [Related]

  • 15. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial.
    Hart RG, Diener HC, Yang S, Connolly SJ, Wallentin L, Reilly PA, Ezekowitz MD, Yusuf S.
    Stroke; 2012 Jun 30; 43(6):1511-7. PubMed ID: 22492518
    [Abstract] [Full Text] [Related]

  • 16. Dabigatran etexilate (Pradaxa) for the treatment of atrial fibrillation.
    Belavic JM.
    Nurse Pract; 2011 Sep 30; 36(9):6-7. PubMed ID: 21857210
    [No Abstract] [Full Text] [Related]

  • 17. Direct oral anticoagulants in atrial fibrillation.
    Noll G, Noll S, Hürlimann D.
    Semin Hematol; 2014 Apr 30; 51(2):139-46. PubMed ID: 24861798
    [Abstract] [Full Text] [Related]

  • 18. Warfarin versus dabigatran etexilate: an assessment of efficacy and safety in patients with atrial fibrillation.
    Dzeshka MS, Lip GY.
    Expert Opin Drug Saf; 2015 Jan 30; 14(1):45-62. PubMed ID: 25341529
    [Abstract] [Full Text] [Related]

  • 19. Dabigatran: safer, more effective and easier to use than warfarin.
    Cardiovasc J Afr; 2009 Jan 30; 20(5):311-2. PubMed ID: 19907807
    [No Abstract] [Full Text] [Related]

  • 20. Dabigatran versus warfarin in patients with atrial fibrillation.
    Tomoda H.
    N Engl J Med; 2009 Dec 31; 361(27):2671-2; author reply 2674-5. PubMed ID: 20050382
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.